Innovative
Solutions in
3D Bioprinting
At Polbionica, we develop breakthrough technologies in biofabrication. We provide a comprehensive technological ecosystem for the production and cultivation of advanced tissue structures, organoids, and cellular scaffolds created using 3D bioprinting. Our flagship project is the Bionic Pancreas-ATMP® — the world’s first functional organ bioprinted from living cells, capable of physiological insulin and glucagon secretion. The technology is being developed as a novel therapeutic strategy for type 1 diabetes and chronic pancreatitis. Our innovations support and accelerate research in regenerative medicine, personalized therapies, and drug testing, opening new opportunities for the development of advanced treatment strategies. We equip scientists and clinicians with tools for designing and evaluating tissue models used in preclinical research and therapeutic development.
We are a research center, specialized in software development
Lorem ipsum dolor sit amet, purto recusabo cu nam, omnes sadipscing ei pro. Alia nonumy saperet eu sea. Tation euripid eu per, nullam putant tamquam cum cu. Mei velit causae ex.
Advancing the Bionic Pancreas — Because the Future Starts Today
Bionic means living and functional. Our Bionic Pancreas-ATMP® is the world’s first organ fabricated using 3D bioprinting technology, incorporating proprietary TintBionic® and Printiss® bioinks, pancreatic islets, and — in later stages — patient-derived stem cells.
Thanks to full vascularization and the ability to physiologically secrete insulin and glucagon, the bionic pancreas has the potential to replace the natural organ and serve as a viable therapeutic alternative for treating type 1 diabetes and chronic pancreatitis. This technology marks the beginning of a new era in regenerative medicine.
Following the successful completion of preclinical studies, we are preparing for clinical trials aimed at evaluating therapeutic efficacy.
Delivering Key Products for the Advancement of 3D Bioprinting
Precise fabrication of three-dimensional living cell structures requires advanced bioinks designed specifically for 3D bioprinting. These materials are essential for maintaining structural fidelity while providing a supportive environment for cell development.
Our proprietary bioinks from the TintBionic®, CleanCure™, and Printiss® product lines are engineered for tissue engineering applications. Their broad spectrum of biophysical properties enables the creation of stable scaffolds and microenvironments that promote cell adhesion, growth, and differentiation — forming a critical foundation for modern bioprinting of organs, organoids, and tissue models.
ResearchLine™ Bioreactor — Advanced Platform for In Vitro Tissue Model Culture
ResearchLine™ is an innovative research bioreactor designed for the cultivation and incubation of 3D tissue models and bionic organs in vitro. The system enables precise environmental control for the development of vascularized structures, supporting functional studies and cell viability assessment.
This globally unique solution allows researchers to evaluate biological model responses to defined physicochemical parameters and biologically active compounds introduced into the culture medium. Built-in automation of monitoring and control processes ensures reproducibility and standardization of culture conditions — essential for advancing regenerative medicine, pharmacology, and cell biology research.
what we are currently doing
Projects
Awards & Recognitions
European Commission – Seal of Excellence
Horizon Europe | EIC Accelerator (2023)
Horizon 2020 | SME Instrument (2020)
Project: 3D-bioprinted bionic pancreas as a cure for type 1 diabetes
